Lantern Pharma announces roadmap for withZeta.ai AI platform expansion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmi
May 7, 2026 9:01 AM EDTPlanned additions are designed to expand and enhance withZeta.ais capabilities, including: real-time, multi-omic computational analyses; simultaneous, highly parallel multi-agentic reasoning, and enterprise-grade institutional deployment. withZeta.ai is now commercially available with a fully enabled subscription payment model serving the full spectrum of the biomedical research and drug development community and representing a new, non-dilutive revenue stream for Lantern Pharma shareholders in a market for AI-focused drug development and discovery tools and services valued at nearly $15 billion USD.
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ:... More
